{"nctId":"NCT01306214","briefTitle":"Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus","startDateStruct":{"date":"2011-02"},"conditions":["Diabetes Mellitus, Type 2","Obesity"],"count":566,"armGroups":[{"label":"BI 10773 low dose","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo","Drug: BI 10773"]},{"label":"BI 10773 high dose","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo","Drug: BI 10773"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"BI 10773","otherNames":[]},{"name":"BI 10773","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Diagnosis of T2DM prior to informed consent\n2. Male and female patients on diet and exercise regimen who are pre-treated with multiple daily injections (MDI) of insulin alone or in combination with immediate or extended release metformin\n3. Stable metformin therapy: daily dose \\>=1500 mg/day or maximum tolerated dose\n4. HbA1c \\>=7.5% and \\<=10% at screening\n\nExclusion criteria:\n\n1. Uncontrolled hyperglycemia with a glucose level \\>240 mg/dl (\\>13.3 mmol/L) after an overnight fast during placebo run-in\n2. Any contraindications to metformin according to the local label\n3. Acute coronary syndrome, stroke or TIA within 3 months prior to informed consent","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in HbA1c After 18 Weeks of Treatment","description":"The primary endpoint was the change from baseline in HbA1c after 18 weeks of treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.50","spread":"0.05"},{"groupId":"OG001","value":"-0.94","spread":"0.05"},{"groupId":"OG002","value":"-1.02","spread":"0.05"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Insulin Dose After 52 Weeks of Treatment","description":"The secondary endpoint is change from baseline in insulin dose after 52 weeks of treatment","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.16","spread":"2.16"},{"groupId":"OG001","value":"1.33","spread":"2.13"},{"groupId":"OG002","value":"-1.06","spread":"2.14"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight After 52 Weeks of Treatment","description":"The secondary endpoint was the change from baseline in body weight after 52 weeks of treatment","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.44","spread":"0.36"},{"groupId":"OG001","value":"-1.95","spread":"0.36"},{"groupId":"OG002","value":"-2.04","spread":"0.36"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HbA1c After 52 Weeks of Treatment","description":"The secondary endpoint was the change from baseline in HbA1c after 52 weeks of treatment","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.81","spread":"0.08"},{"groupId":"OG001","value":"-1.18","spread":"0.08"},{"groupId":"OG002","value":"-1.27","spread":"0.08"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":22,"n":188},"commonTop":["Hypoglycaemia","Nasopharyngitis","Urinary tract infection","Diarrhoea","Back pain"]}}}